INTRATYMPANIC INJECTIONS AND MENIERE DISEASE: is there a consensus today?

Marie-José FRAYSSE, MD
Otology and Otoneurology department
University Hospital - TOULOUSE

IFOS COURSE
HO CHI MINH CITY
24/27 Nov 2019
INTRODUCTION

- Menière’s disease (MD) is characterized by idiopathic endolymphatic hydrops (EH) and results in repeated attacks of vertigo, hearing loss, tinnitus, and aural fullness in the affected ear.

- Numerous treatments exist but aren’t ideal without identifying causes

- The conservative treatment is, in some cases, insufficient

- In this context ITI became unavoidable within the therapeutic spectrum of options.
INTRODUCTION

To propose ITI to a patient with MD implies the following considerations:
- Being confident with the diagnosis
- Having tried various types of classical treatments
- Evaluating the functional disability of the patient

Which product to inject? Based on bibliography and experience
Which protocol to be used? Explain to the patient importance of the follow-up

Not forgetting that treatments are designed for controlling symptoms and improving life quality.
Pathophysiology
Ménière disease

- Based on the Hydrops endolymphatic (HE) in histology and on MRI protocol hydrops (Gado 4h acquisition)

- HE doesn’t explain everything: asymptomatic forms, large variety of symptoms and remission duration.
ITI principal and Ménière disease

➢ Diffusion at FR and FO windows level
➢ Allowing high concentration (x 260) of injected product without side effects from the systemic treatment
➢ Non invasive method, external, localized side effects uncommon
➢ Abundant literature, Gentamicin has an indisputable effect
➢ Corticosteroid: which mode of action? Few studies existing versus placebo effect
➢ Recent publications compare Gentamicin effects to corticosteroid’s (Dexamethasone or Methylprednisolone)
➢ Where do we really stand?

Which protocols in 2019?
Therapeutic recommendations sforl 2016

- **1st period**: Medical treatment and hygiene/dietary measurements (low invasiveness)

- **2nd period**: ITI of corticoids and/or Sac surgery (low invasiveness)

- **3rd period**: Treatment of the vestibular function (gentamicin - high invasiveness)

- **4th period**: Suppressor treatments of all vestibular functions (surgical labyrinthectomy or vestibular neurotomy - maximum invasiveness).
ITI INDICATIONS: 3 QUESTIONS

DECISION CRITERIA:

- Is it surely a Meniere disease?
- Is the Meniere disease disabling for the patient?
- All available solutions have been tried out?
Definite Ménière’s disease:

A. Two or more spontaneous episodes of vertigo lasting 20 minutes to 12h

B. Audiometrically documented low to medium frequencies SNHL in the affected ear on at least one occasion before, during or after one of the episodes of vertigo

C. Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear

D. Other causes made unlikely
Probable Ménière's disease:
A. At least two episodes of vertigo or dizziness 20 min – 24 hours in duration
B. Fluctuating aural symptoms (hearing, tinnitus or aural fullness) in the affected ear
C. Other causes made unlikely.

Vestibular migraine: Diagnostic criteria

Consensus document of the Bárány Society and the International Headache Society

Thomas Lempert\textsuperscript{a*}, Jes Olsen\textsuperscript{b}, Joseph Furman\textsuperscript{c}, John Waterston\textsuperscript{d}, Barry Seemungal\textsuperscript{e}, John Carey\textsuperscript{f}, Alexander Bisdorff\textsuperscript{g}, Maurizio Versino\textsuperscript{b}, Stefan Evers\textsuperscript{h} and David Newman-Toker\textsuperscript{b}

\textsuperscript{a}Department of Neurology, Schlosspark-Klinik, Berlin, Germany

Table 1. Current definitions of vestibular migraine and Menière’s disease.

<table>
<thead>
<tr>
<th>Vestibular migraine</th>
<th>Menière’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) At least five episodes with vestibular symptoms of moderate or severe intensity, lasting 5 minutes to 72 hours</td>
<td></td>
</tr>
<tr>
<td>(b) Current or previous history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)</td>
<td></td>
</tr>
<tr>
<td>(c) One or more migraine features with at least 50% of the vestibular episodes:</td>
<td></td>
</tr>
<tr>
<td>- headache with at least two of the following characteristics: one-sided location, pulsating quality, moderate or severe pain intensity, aggravation by routine physical activity</td>
<td></td>
</tr>
<tr>
<td>- photophobia and phonophobia</td>
<td></td>
</tr>
<tr>
<td>- visual aura</td>
<td></td>
</tr>
<tr>
<td>(d) Not better accounted for by another vestibular or ICHD diagnosis</td>
<td></td>
</tr>
<tr>
<td>(a) Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours</td>
<td></td>
</tr>
<tr>
<td>(b) Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear on at least one occasion before, during or after one of the episodes of vertigo</td>
<td></td>
</tr>
<tr>
<td>(c) Fluctuating aural symptoms (hearing, tinnitus, or fullness) in the affected ear</td>
<td></td>
</tr>
<tr>
<td>(d) Not better accounted for by another vestibular diagnosis</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Lempert et al. (11) for vestibular migraine and Lopez-Escamez et al. (22) for Menière’s disease.
Diagnostic criteria for Vestibular Migraine (VM)
Barany society

Vestibular migraine

A. At least 5 episodes with vestibular symptoms with moderate to severe intensity and lasting from 5 minutes to 72 hours.

B. Antécédents current or past migraines with or without aura according to ICHD;

C. One or several migraine phenomenon accompanying at least 50% of vestibular episodes:
   - headaches with at least 2 of the following characteristics: unilateral localization, pulsating, moderate to severe pain, aggravation due to basic physical activities,
   - photophobia and phonophobia,
   - Visual aura;

D. No better explanation through other vestibular or ICHD diagnosis.
Diagnosis criteria from Barany society

Vestibular migraine most likely type:

A. At least 5 episodes with vestibular symptoms with moderate to severe intensity, going from 5 minutes to 72 hours;

B. Only one of B and C criterion for vestibular migraine is for-filled (antecedents of migraine or migraine phenomenon during the episode);

C. No better explanation through another vestibular or ICHD diagnosis.

https://content.iospress.com/download/journal-of-vestibular-research/ves00453?id=journal-of-vestibular-research%2Fves00453
Differential diagnosis: Ménière’s disease

Therefore sometimes difficult to assess based on a spectrum of arguments:

- Clinical history +++
- Related signs, triggers,
- Clinical exam,
- Deafness evolution

Differential diagnosis: VM and Ménière’s disease

- Signs and symptoms can often be correlated

- In favor of VM:
  - Short crisis < 15 minutes or longer > 24 h
  - Photo-phonophobia, anxiety, frequent palpitations
  - High visual sensitivity
  - Signes centraux from clinical exam +++
  - Fluctuating deafness ON LOW FRQUEoften bilaterally but rarely permanent nor evolutive. +++

+++
2/ Is it actually disabling? Every options have been explored?

1/ Crisis: frequency (6 months to 1 year)

2/ Tumarkin attacks = Major criteria

3/ Handicap evaluation
   - Anxiety, stress: HADS survey
   - Vertigos: intensity and survey DHI, AAO-HNS
   - Professional impact (sick leave)
   - Driving forbidden ?

Table 3.5. Échelle de niveau fonctionnel en six stades.

1. Ma maladie vertigineuse n'a aucun retentissement sur mes activités.
2. Quand j'ai un vertige, je dois arrêter mes activités pour un certain temps, mais le vertige s'arrête rapidement et je peux les reprendre. Je continue à travailler, à conduire, et m'implique dans la plupart de mes activités. Je n'ai pas eu besoin d'aménager mes projets ni de faire certaines adaptations de mes activités à cause de mes vertiges.
3. Quand j'ai un vertige, je dois arrêter mes activités pour un certain temps, mais le vertige finit par s'arrêter et je peux reprendre mes activités. Je continue à travailler, à conduire, et m'implique dans la plupart de mes activités. J'ai dû aménager mes projets et adapter mes activités à cause de mes vertiges.
4. Je suis capable de travailler, conduire, m'occuper de ma famille, de m'impliquer dans la plupart de mes activités, mais cela me demande constamment des efforts importants, et d'économiser mon énergie.
5. Je suis incapable de travailler, de conduire, de m'occuper de ma famille, ou de m'impliquer dans la plupart des activités que j'avais l'habitude de faire. Même les activités essentielles me sont difficiles à réaliser. Je suis handicapé.
6. J'ai arrêté de travailler depuis 1 an ou plus et/ou je touche une indemnisation à cause de mes problèmes de vertiges ou déséquilibré.
3/ Every options have been explored?

1 /Evaluation of anterior treatments «classical»
   - Bétahistine, Méclozine, Flunarizine, Acétyl-leucine
   - Oral steroids
   - Osmotic treatments: diuretics (Acétazolamide, Furosémide), (Glycérol)

2 /If any doubt do not hesitate testing migraine prophylactic treatment
   Flunarizine, Propanolol 40 to 80 mg, Amitriptyline, Vérapamil

3 /If emotional context: reinsure, explanation, BCT, relaxation therapy, etc.
ITI CORTICOSTEROIDS

We know:

1/ Glucocorticoids receptors existing présents at cochlea level, vestibular and spiral ligament

2/ Auto-immuns complexes have been identified at endolymphatic sac level (IgG deposit, antibodies anticollagene type II and endolymphatic bag)

3/ Aquaporins (transmembrane proteins) have been identified in the utricule, are sensitive to glucocorticoids

4/ Few randomized clinical trials have highlighted significant effect with 2 years follow-up compared to placebo.

5/ Most used concentration is 4mg/ml 1ITI/day with a 3 to 5 ITT blocks (DEXA)

6/ Alternative option methylprednisolone at 67,5 mg 2 to 3 ITT according to literature
# Intratympanic corticosteroids in Ménière’s disease: A mini-review

Mitesh Patel  
Division of Brain Sciences, Imperial College London, Charing Cross Hospital, London, W6 8RF, UK  
Received 9 April 2017; revised 27 May 2017; accepted 1 June 2017

Table 1  
Summary of studies meeting inclusion criteria on the effectiveness of intratympanic steroid injections in Ménière’s disease over 2-years. Class A (complete) vertigo control was used as the primary outcome in this Review.

<table>
<thead>
<tr>
<th>Study</th>
<th>Steroid type</th>
<th>Conc. (mg/ml)</th>
<th>Treatment protocol</th>
<th>Further injections offered</th>
<th>Study type</th>
<th>Sample size</th>
<th>Percentage of patients with Class A vertigo control (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrs, 2004</td>
<td>Dex</td>
<td>10</td>
<td>1 injection for 4 consecutive weeks</td>
<td>Yes</td>
<td>Retrospective</td>
<td>34</td>
<td>24</td>
</tr>
<tr>
<td>Garduno-Anaya et al., 2005</td>
<td>Dex</td>
<td>4</td>
<td>1 injection daily for 3 consecutive days</td>
<td>No</td>
<td>Prospective</td>
<td>11</td>
<td>82</td>
</tr>
<tr>
<td>Boleas-Aguirre et al., 2008</td>
<td>Dex</td>
<td>12</td>
<td>1 injection</td>
<td>Yes</td>
<td>Retrospective</td>
<td>129</td>
<td>91*</td>
</tr>
<tr>
<td>Herrera et al., 2010</td>
<td>Methylpred</td>
<td>40</td>
<td>1 injection for 3 consecutive days</td>
<td>Yes</td>
<td>Prospective</td>
<td>29</td>
<td>78</td>
</tr>
<tr>
<td>Casani et al., 2012</td>
<td>Dex</td>
<td>4</td>
<td>1 injection over 3 consecutive days</td>
<td>Yes</td>
<td>Prospective</td>
<td>28</td>
<td>43</td>
</tr>
<tr>
<td>Martin-Sanz et al., 2013a</td>
<td>Dex</td>
<td>4</td>
<td>1 injection weekly for 3 consecutive weeks</td>
<td>No</td>
<td>Prospective</td>
<td>53</td>
<td>15.1</td>
</tr>
<tr>
<td>Martin-Sanz et al., 2013b</td>
<td>Dex</td>
<td>4</td>
<td>1 injection daily for 3 consecutive days or 1 injection for 3 consecutive weeks</td>
<td>Yes</td>
<td>Retrospective</td>
<td>22/34</td>
<td>40.9/44.1</td>
</tr>
<tr>
<td>MeRackan et al., 2014</td>
<td>Dex</td>
<td>24</td>
<td>1 injection, 3 doses delivered 10 min s apart</td>
<td>Yes</td>
<td>Retrospective</td>
<td>159</td>
<td>81.1b</td>
</tr>
<tr>
<td>She et al., 2015</td>
<td>Methylpred</td>
<td>20</td>
<td>1 injection over 10 consecutive days</td>
<td>No</td>
<td>Retrospective</td>
<td>16</td>
<td>81</td>
</tr>
<tr>
<td>Albu et al., 2016</td>
<td>Dex</td>
<td>4</td>
<td>1 injection over 3 consecutive days or 1 injection over 3 consecutive days + high-dose betahistine</td>
<td>Yes</td>
<td>Prospective</td>
<td>32/30</td>
<td>44/73.3</td>
</tr>
<tr>
<td>Patel et al., 2016</td>
<td>Methylpred</td>
<td>62.5</td>
<td>1 injection fortnightly (1 course = 2 injections)</td>
<td>Yes</td>
<td>Prospective</td>
<td>30</td>
<td>70</td>
</tr>
<tr>
<td>Leng et al., 2017</td>
<td>Dex</td>
<td>5</td>
<td>1 injection for 4 consecutive days, over 4 consecutive weeks</td>
<td>Yes</td>
<td>Retrospective</td>
<td>23</td>
<td>73.9</td>
</tr>
</tbody>
</table>

Dex = Dexamethasone; Methylpred = Methylprednisolone.
5. Conclusion

If Meniere's disease patients continue to experience attacks of vertigo despite dietary management or oral medication, intratympanic steroid may be used as an as-needed therapy. With steroid, there is little risk of hearing loss, chronic symptoms of dizziness resulting from the fixed vestibular loss or adverse events. As many patients with Ménière's disease are frail or experience anxiety that complicates ablative therapy, intratympanic steroid is an excellent option. That said, clinicians must decide the appropriate treatment in concordance with the patient's expectation as intratympanic steroid treatment may need to be repeated periodically.
1 / **Ototoxic effect:** induce a stable and constant deficit allowing vestibular centers to compensate the deficit

2 / Effect on **vertigo long term management has been demonstrated** (numerous publications and meta-analyses) 75 to 90 % of vertigo control

3 / **Low hearing impact risk**, with low dose protocol remains (no consensus).

4/ **Compensation difficulties** regarding vestibular deficit induced by ITI of gentamicin have to be taken into consideration.

Which protocol?

*To be used according to well defined criteria*
Intratympanic (IT) Therapies for Menière’s Disease: Some Consensus Among the Confusion

Desi P. Schoo · Grace X. Tan · Matthew R. Ehrenburg · Seth E. Pross · Bryan K. Ward · John P. Carey

ITT of Gentamicin: Fine vertigo control (85 to 90% of the time) with moderate risk for audition with ‘low dose’ protocols or via titration and spaced ITT, however the risk does exist.

ITT of Corticoids: Lack of consensus, various protocols and very variable results.

Randomized studies Gentamicin/Corticosteroids
108 articles analyzed
## Dexamethason versus Placebo

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Outcome</th>
<th>Dexamethasone (Dxa)</th>
<th>Placebo</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garduño-Anaya et al., 2005</td>
<td>Prospective, randomized, Open, n = 22, follow-up 2 yrs</td>
<td>Vertigo CC*</td>
<td>Dxa: 82%</td>
<td>Placebo: 57%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>THI Tinnitus</td>
<td>Dxa: 48%</td>
<td>Placebo: 20%</td>
<td></td>
</tr>
</tbody>
</table>

## Steroids vs Gentamicin

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Outcome</th>
<th>Gentamicin (Genta)</th>
<th>Methylprednisolone (MéthylP)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabra et Saliba, 2013</td>
<td>Retrospective, n = 89, follow-up 2 yrs</td>
<td>Vertigo CC*</td>
<td>Genta: 87%</td>
<td>MéthylP: 48%</td>
<td>No différence Genta / MéthylP</td>
</tr>
<tr>
<td>Patel et al., 2016</td>
<td>Prospective, randomized, Dble aveugle, n = 60, 2yrs</td>
<td>Vertigo CC*</td>
<td>Genta: 87%</td>
<td>MéthylP: 90% (20% réinjection)</td>
<td>No différence Genta / MéthylP</td>
</tr>
<tr>
<td>Casani et al., 2012</td>
<td>Prospective, randomized, Open, n = 60</td>
<td>Vertigo CC*</td>
<td>Genta: 93%</td>
<td>Dexamethasone (Dexa): 61%</td>
<td>No différence Genta / Dexamethasone</td>
</tr>
</tbody>
</table>

**CC**: complete vertigo control AAO-HNS criteria ; **CC***: idem, classe A + B ; **PTA**: Pure tone audiometry

**Dexa**: Dexamethasone ; **MéthylP**: Methylprednisolone
Objective: To evaluate outcomes of intratympanic (IT) dexamethasone and gentamicin in Ménière Disease (MD).

Methods: Charts of adult patients with unilateral definite MD receiving IT gentamicin or dexamethasone for vertigo control were retrospectively reviewed. All patients had at least 6 months follow-up. Failure in each group was defined as requiring more aggressive therapy.

To 2011, all patients received IT gentamicin, administered as primary therapy after failure of conservative treatment. Gentamicin was administered every 2 weeks, up to three injections, until vertigo control was achieved. In 2011, the treatment protocol shifted to IT dexamethasone as initial treatment, with gentamicin used for dexamethasone failures. Dexamethasone was administered weekly for up to three injections. Treatments could be repeated if symptoms worsened.

Results: Thirty-three patients received IT dexamethasone, and 70 patients received IT gentamicin. Dexamethasone received a mean of 3.3 injections compared to 2.7 in the gentamicin group ($P = 0.011$). There were 12 (37%) dexamethasone group failures and only seven (10%) gentamicin failures ($P = 0.025$). No patients failed both treatments. The time to failure in the dexamethasone group was 5 months, whereas in the gentamicin group it was 27 months. Bone audiometry from baseline was not different between treatment groups ($P = 0.30$).

Conclusion: Subjects receiving IT gentamicin required fewer injections and had a significantly longer time to failure than dexamethasone. Audiometric outcomes were similar between the groups. The use of IT gentamicin as initial therapy and long-term control of MD is safe and effective.

Key Words: Ménière disease, gentamicin, intratympanic therapy.

Level of Evidence: 3
➢ Some are fond of gentamicin 'low dose' because results on vertigos are better and more lasting in time.

➢ Current tendency is to propose ITI Steroids in the first place since recent studies.

➢ To ponderate with experience:
  ➢ Dexa is a good option to wait for another stage, however most of the time the disease keeps evolving and reinfections are required. *(how often? When should we consider the treatment as a failure?)*
  ➢ Genta most of the time « stops » the disease with stable vertigo and deafness results but is destructive for the vestibule and demonstrates a very low but existing risk for audition.

*Has to be well explained to the patient*
In practice

**Conservative treatment**: Dexamethasone

- If Deafness with a PTA < 50 dB
- If low or no vestibular deficit to caloric tests (<50%)
- If hearing loss or high vestibular deficit on contralateral ear.
- For all patients suspected with low vestibular compensation (elderly patients)
- If Meniere and vestibular migraine entangled ++++

**Ablative treatment**: Gentamicin

in other cases and when the handicap is severe. Discussion is required
Ablative solution with gentamicin

1/ ITT of gentamicin 1st to be considered:
- If Tumarkin attacks
- If PTA and/or severe vestibular deficit with a regular controlateral ear and Meniere disease diagnosis defined and patient highly disabled with no other signs that could interfere with compensation.

2/ ITT de gentamicin 2nd to be considered:
- If failure of the ITT of dexamethasone
  ➢ The patient has to be informed that the potential vestibular deficit creates post-treatment instability which implies a required vestibular reeducation.
ITI Dexamethasone

➢ Under microscope, posterior mesotymapnic injection with a spinal needle of 25 GA (0,50x90mm) and a syringe of 1ml

➢ Ambulatory treatment under local anesthesia (prilocaine)

➢ Dexamethasone 4mg/ml 0,4 to 0,6 ml per injection

➢ An injection per day for 3 days

➢ The patient has to remain lying down in lateral decubitus for 40 minutes after injection.

➢ Systematic control at 3, 6, 12 and 24 months.
ITI Dexaméthasone: Results

Evaluation at 3, 6 & 12 months

→ If failure, 2ème course
→ If failure, discussion Gentamicine

25 patients

- 23 Complete control (92%)
- 2 Failure

A 6 months: n=25

- 15 Complete control (70%)
- 4 not controlled

A 1 year: n=19

- 4 Complete control (20%)
- 14 controlled with second course Deka

A 2 ans: n=19

- 1 not controlled

Genta (n=2), Dexa (n=2) second course

Follow up < 2 years, n=8, Deka

Genta (n=1)
ITI Dexamethasone: Results

Evaluation at 6, 12 and 24 months

- If vertigos remain, 2nd series of injection
- If vertigos persist, discuss Gentamicin injections

At 6 months n=25

- 23 Contrôle complet 92%
- 2 échecs

At 1 year n=23

- 17 Contrôle complet 70%
- 6 non contrôlés

At 2 years n=19

- 4 Contrôle complet 20%
- 13 contrôlés après un 2ème traitement dexam
- 1 non contrôlé

Genta n=2
Genta (n=3), Dexa (n=3) 2nd series
Genta (n=1)
ITI Dexamethasone synthesis

25 patients

- **Whith only Initial treatment**
  
  Vertigo Control class A:  
  
  - 92% at 6 months (n=25)
  
  - 70% at 1 year (n=20)
  
  - 20% at 2 years (n=19)

- **After one or 2 re-injections**  
  
  56% patients more controlled at 2 years in total 76%

- 24% of patients had ITI of Gentamicine during this time
ITT Gentamicin

- **Gentamicin concentration 40mg/ml**, 0.4 to 0.6 ml for each ITI

- **Dose to be injected?**

*Outcomes of intratympanic Gentamicin injection to treat Meniere’s disease* Leh-Kiong-Hun 2012, Otol Neurotol

- 13.4 mg total dose injected, low threshold under which results are significantly less efficient toward vertigos control.

- 1 ITI at 40 mg/ml should be of at least 0.4 to 0.5 cc to be considered efficient
CURRENT протокол

MIXT протокол: low dose/Titration

- 1 инъекция ➔ контроль между J21 и J30. Если:
  - клинические признаки нового баланстального дефекта
  - новый кризис
  - Дефект ≥ 75 to 80 % на калорическом тесте

- и контроль через 3, 6, 12, 24 месяца с аудиометрией, калорическим тестом, VHIT и PEMV

- Если новый кризис ➔ 2-й курс ИТИ с тем же протоколом.

{ STOP инъекции если 2 или 3 критерий }
Vertigo Control (Criteria AAO-HNS)

Mean follow-up: 76 months

- Classe A: Complete control 79%
- Classe B: Substantial control 8%
- Classe C: Partial control 6%
- Classe D: no change 5%
- Loss track 1 patient

53 patients
Improvement average: 26 dB (13 to 40 dB)
Aggravation average: 21 dB (14 to 29 dB)
No complete or deep deafness observe

Hearing results

53 patients

Improvement (>10dB) 81%
Stability
Aggravation (>10dB) 19%
Hearing evolution at 5 years compared to contra lateral hearing

C. Tavernier

32 patients

**PAM**

<table>
<thead>
<tr>
<th>INTERVAL</th>
<th>PRE-TREATMENT</th>
<th>POST-TREATMENT</th>
<th>FOLLOW-UP &gt; 5 ans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Côté non injecté</td>
<td>-20.0</td>
<td>-15.0</td>
<td>-10.0</td>
</tr>
<tr>
<td>Côté injecté</td>
<td>-30.0</td>
<td>-25.0</td>
<td>-20.0</td>
</tr>
</tbody>
</table>

Différence d'évolution: p=0.20
No significant statistical deviation as a function of the injection protocol (p=0,57)

A vestibular reeducation is most of the time required
Long-term Vertigo Control and Vestibular Function After Low-dose On-demand Transtympanic Gentamicin for Refractory Menière's Disease

- Average follow-up 4.8 years (from 2 to 8 years) retrospective
- Vestibular average deficit over caloric test:
  - Pre-treatment deficit = 51.4 (SD = 17)
  - Maximum deficit = 87.9 (SD = 13)
  - Long term deficit = 85.3 (SD = 15)

Vestibular deficit is increased post ITI of gentamicin and remains stable during the long term follow up

Def pre : pre-treatment deficit; Def max : maximum deficit; Def LT : long term deficit
* : significant variation
Correlation between vertigo recurrence / caloric tests variations over time
Results: evolutive profiles

- **« Successful » group** stable and deep deficit > 80%

- **« Recurrence » group**
  
  4/10 patients with fluctuant and average deficit
Take home message  /  ITI Ménière’s disease

- 1/ Menière disease and vestibular migraine can often coexist. Warning!

- 2/a Dexamethasone is the treatment to be considered in the first place especially if the hearing is preserved (1 to 2 blocks of 3 ITI each);

- 2/b If recurrence in time provided after intermediate period of good results, ITI can be renewed (« as needed » protocol to be discussed with patient versus ITI of Genta)

- 3/ It’s important that caloric tests and VHIT are achieved before ITI in order to evaluate vestibular status with both ears.

- 4/ Gentamicin protocols low dose are efficient with no risks, especially no major hearing risk. (PTA>40dB)

- 5/ A vestibular rehabilitation has to be proposed post ITT of Gentamicin
TAKE HOME MESSAGE

6/ If recurrences with Gentamicin, reevaluate the vestibular function with caloric tests
   It is an option to reinject gentamicin.

7/ In the reinjection case, PTA remains stable if low dose gentamicin protocol is thoroughly followed.

8/ It’s crucial to inform the patient on its treatment options, risks and long-term follow-up.
Thanks for your attention

If you have any questions?

You can contact me at:

fraysse.mj@chu-toulouse.fr
estevefraysse@yahoo.fr
La Migraine vestibulaire n’est pas une indication d’ITT.
Si MV et MM associées essayez d’abord les ttt de la Migraine vestibulaire.
Si MV et MM associés et échec des ttt : attention à la Gentamicine car risque de bi latéralisation. Préférez les ITT de corticoïdes si les signes de Maladie de Ménière sont prédominants.

Indispensable de bien connaître les critères Dc actuels de la Barany society des 2 maladies ++++